Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 58 for “"CAR-T"”.
-
Development of a canine model to evaluate CAR-T cell subsets
… Immunotherapy with chimeric antigen receptor (CAR) T cells has demonstrated success in human blood cancers, although relapse occurs in ~50% of patients. In the context of solid tumors, CAR-T cells show only transient effects. As a "living therapy", development of the next generation CAR-T cells …
-
Multi-Pronged Approach to Understanding the Toxicity Associated with CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has revolutionised cancer immunotherapy, providing effective treatment for previously untreatable malignancies. Its success, in treat ment of haematological cancers, is now fast-advancing to solid tumours. Though, these efforts are faced with many …
-
Engineering VHH-based chimeric antigen receptor (CAR) T cell therapy for solid tumor treatment
Chimeric antigen receptor (CAR) T cells are a promising cancer therapeutic, as they can specifically redirect the cytotoxic function of a T cell to a chosen target of interest. CAR T cells have been successful in clinical trials against hematological cancers, but have experienced low efficacy …
-
TOX2 and TOX at the intersection of central memory and exhaustion in human CAR T cells
CAR T therapy has provided a breakthrough in the treatment of hematologic malignancies, showing remarkable efficacy in cancers such as leukemia and lymphoma. However, the success of CAR T therapy in treating solid tumors has been limited due to T cell exhaustion, which limits their proliferation …
-
Generation of a novel pan-cancer chemokine receptor-modified CAR-T cell therapy directed towards nfP2X7
CAR-T cell therapy has achieved significant success in the treatment of multiple haematological malignancies. However, solid cancers present challenges such as tumour antigen heterogeneity and complex mechanisms of immune evasion that have limited the translation of CAR-T cell therapies from …
-
CAR-T και Antibody–Drug Conjugates στη σύγχρονη ογκολογία: Φαρμακοεπαγρύπνηση, προφίλ ασφάλειας και προκλήσεις στην κλινική εφαρμογή και πρόσβαση
… νέες στοχευμένες θεραπείες, όπως οι κυτταρικές CAR-T και τα Antibody–Drug Conjugates, ADCs, που εμφανίζουν σημαντική ανταπόκριση τόσο στην αντιμετώπιση αιματολογικών κακοηθειών όσο και συμπαγών όγκων. Στην παρούσα εργασία, τονίζεται η σημαντικότητα των νέων ογκολογικών θεραπειών, αναλύοντας …
-
Exploring Veto Activity: DNAM-1-CD155 Axis in Overcoming NK Cell-Mediated Allo-Rejection and Applications for CAR-T Cell Therapy
… of Off-the- shelf Chimeric Antigen Receptor (CAR)-T Therapy: Engineering Anti-Viral Veto CD8+ T Cells”. As demonstrated in our previous research, in a murine model with mild conditioning, anti-third-party central memory CD8+ veto T cells (veto Tcm) can prevent T cell- mediated graft rejection …
-
A Novel, Codon-Based Approach to Preserve On-Tumor Activity and Reduce Off-Tumor Toxicity of Chimeric Antigen Receptor (CAR) T Cells
<p> Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable results in the treatment of various hematological malignancies, ushering in tremendous innovation within the field of immunotherapy and improving patient outcomes. Despite this, CAR-T cell therapy is associated with a …
-
Enhancing Chimeric Antigen Receptor T cell therapy in Mouse EGFRvIII Heterogeneous Glioblastoma
<p>Chimeric antigen receptor (CAR) T cell therapy for glioblastoma remains challenging due to insufficient CAR T cell abundance and antigen-negative tumor cells evading targeting. Unfortunately, most preclinical studies evaluating CAR T cells in glioblastoma use tumors expressing a single antigen, …
-
Leveraging Systems Immunology To Understand The Molecular Underpinnings Of Chimeric Antigen Receptor T-Cell Therapy
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising strategy for the treatment of human cancers, and in the last decade has progressed from breakthrough early trials to first in class FDA approvals for B-cell leukemias and lymphomas. Concurrent with the promise and challenges in cancer …
-
Efficacy of Dual Cd19-Cd79B Car In B-Cell Malignancies
… CD19-targeting chimeric antigen receptor (CAR) T cell therapy. CD19 loss is a major cause of relapse and resistance after CD19 CAR T therapy. Dual antigen targeting could overcome resistance due to antigen escape and improve outcomes after CAR T cell therapy. We hypothesized that dual …
-
In-vitro Glioblastoma Treatment Focusing on Convection Enhanced Delivery
… brain cancer with discouraging standard of care. New methods like convection enhanced delivery and chimeric antigen receptor T cells (CAR-T) are promising treatments that can be translated to glioblastoma. In this study, CAR-T cell flow through a hydrogel was explored in the context of …
-
Transcription factor modulation in T-cells to improve cancer immunotherapy
… T-cells expressing chimeric antigen receptors (CAR-T) effectively treats refractory hematologic malignancies in a subset of patients, but can be limited by the inability of ex vivo culture systems to expand T-cells sufficiently for effective dosing while producing highly active T-cell products. …
-
Δυσλειτουργία του ενδοθηλίου σε ασθενείς που λαμβάνουν θεραπεία με Τ-λεμφοκύτταρα με χιμαιρικό αντιγονικό υποδοχέα
… T-λεμφοκύτταρα με χιμαιρικό αντιγονικό υποδοχέα (CAR-T cells) έχουν βελτιώσει εντυπωσιακά τη θεραπευτική των αιματολογικών κακοηθειών. Το ιδιαίτερο προφίλ τοξικότητάς τους, με το σύνδρομο απελευθέρωσης κυτταροκινών (CRS) και τη νευροτοξικότητα τη σχετιζόμενη με ανοσοδραστικά κύτταρα (ICANS) έχει …
-
Mathematical Modelling of Immuno-Oncology and Related Immunology
… look specifically at Chimeric Antigen Receptor (CAR)-T cell therapy, explore the mechanisms by which this living drug grows and changes inside the body, and explore how and why this process differs so dramatically between patients. </p><p>We develop two ordinary differential equation models -- …
-
Employing T Cells For Antigen Presentation: Role of Ny-Eso-1+ T-Apc Vaccine In Multiple Myeloma
… Combined immunotherapy with NY-ESO-1<sup>+</sup> CAR T cells (TCR mimetic) and an NY-ESO-1 specific T-APC vaccine in myeloma patients may lead to enhanced anti-myeloma efficacy due to improved persistence of the CAR T cells.</p> <p><strong>Materials and Methods</strong>: Using the Sleeping Beauty …
-
Characterizing T Cell Features of Atypical Lymphocytes for the Optimization of Adoptive Immunotherapies
… populations are regulatory T cells (Tregs) and CAR (chimeric antigen receptor-modified) T cells. The functional role of Tregs in the immune system is non-canonical, in that they prevent hyper-inflammation and resolve immunopathology by constraining conventional immune cell effector functions and …
-
Tethered Il-15 to Augment The Therapeutic Potential of T Cells Expressing Chimeric Antigen Receptor: Maintaining Memory Potential, Persistence, and Antitumor Activity
… the expression of a chimeric antigen receptor (CAR). Infusion of CAR-modified T cells for the treatment B-cell malignancies has demonstrated promise in preclinical and clinical trials. These data highlight the ability of infused CD19-specific T cells to be synchronously activated by large …
-
A three-dimensional agent-based model of glioblastoma with applications towards in vitro and in vivo therapy simulation
… are treated using a uniform standard of care regardless of tumor subtype. To identify subtype-dependent features influencing tumor progression and response to treatments, we developed a three-dimensional agent-based model of glioblastoma. The model incorporates rules governing cell …
-
Utilizing in vivo genome-wide CRISPR/Cas9 screens in immunocompetent mouse models to identify novel tumor liabilities and explore mechanisms of resistance to Chimeric Antigen Receptor T-cell therapy
… (GBM) where most patients, even with standard of care treatment, are dead within 1 year of diagnosis. This lack of effective treatment for GBM reflects formidable challenges to therapeutic design including vast intra- and inter-tumoral heterogeneity, highly invasive growth patterns, and a hostile, …
Page 1 of 3